Tue, October 27, 2020

David Nierengarten Upgraded (ANAB) to Buy and Increased Target to $35 on, Oct 27th, 2020

  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. and-increased-target-to-35-on-oct-27th-2020.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
  • 🞛 This publication is a summary or evaluation of another publication
  • 🞛 This publication contains potentially derogatory content such as foul language or violent themes
David Nierengarten of Wedbush, Upgraded "AnaptysBio, Inc." (ANAB) to Buy and Increased Target from $20 to $35 on, Oct 27th, 2020.

David has made no other calls on ANAB in the last 4 months.



There is 1 other peer that has a rating on ANAB. Out of the 1 peers that are also analyzing ANAB, 0 agree with David's Rating of Hold.



This is the rating of the analyst that currently disagrees with David


  • Yatin Suneja of "Guggenheim" Upgraded from Hold to Strong Buy and Held Target at $36 on, Wednesday, October 14th, 2020